Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity
Kathleen E. Houlahan, Aziz Khan, Noah F. Greenwald, Cristina Sotomayor-Vivas, Robert B. West, Michael Angelo, Christina Curtis
Abstract
Tumors with the same diagnosis can have different molecular profiles and response to treatment. It remains unclear when and why these differences arise. Somatic genomic aberrations occur within the context of a highly variable germline genome. Interrogating 5870 breast cancer lesions, we demonstrated that germline-derived epitopes in recurrently amplified genes influence somatic evolution by mediating immunoediting. Individuals with a high germline-epitope burden in human epidermal growth factor receptor 2 (HER2/ ERBB2 ) are less likely to develop HER2-positive breast cancer compared with other subtypes. The same holds true for recurrent amplicons defining three aggressive estrogen receptor (ER)–positive subgroups. Tumors that overcome such immune-mediated negative selection are more aggressive and demonstrate an “immune cold” phenotype. These data show that the germline genome plays a role in dictating somatic evolution.